Randomized Ablation Strategies for the Treatment of Persistent Atrial Fibrillation

Author:

Dixit Sanjay1,Marchlinski Francis E.1,Lin David1,Callans David J.1,Bala Rupa1,Riley Michael P.1,Garcia Fermin C.1,Hutchinson Mathew D.1,Ratcliffe Sarah J.1,Cooper Joshua M.1,Verdino Ralph J.1,Patel Vickas V.1,Zado Erica S.1,Cash Nancy R.1,Killian Tony1,Tomson Todd T.1,Gerstenfeld Edward P.1

Affiliation:

1. From the Cardiovascular Division (S.D., F.E.M., D.L., D.J.C., R.B., M.P.R., F.C.G., M.D.H., J.M.C., R.J.V., V.V.P., E.S.Z., N.R.C., T.K., T.T.T., E.P.G.), Hospital of the University of Pennsylvania, and the Center for Clinical Epidemiology and Biostatistics (S.J.R.), University of Pennsylvania, Philadelphia, PA.

Abstract

Background— The single-procedure efficacy of pulmonary vein isolation (PVI) is less than optimal in patients with persistent atrial fibrillation (AF). Adjunctive techniques have been developed to enhance single-procedure efficacy in these patients. We conducted a study to compare 3 ablation strategies in patients with persistent AF. Methods and Results— Subjects were randomized as follows: arm 1, PVI + ablation of non-PV triggers identified using a stimulation protocol (standard approach); arm 2, standard approach + empirical ablation at common non-PV AF trigger sites (mitral annulus, fossa ovalis, eustachian ridge, crista terminalis, and superior vena cava); or arm 3, standard approach + ablation of left atrial complex fractionated electrogram sites. Patients were seen at 6 weeks, 6 months, and 1 year; transtelephonic monitoring was performed at each visit. Antiarrhythmic drugs were discontinued at 3 to 6 months. The primary study end point was freedom from atrial arrhythmias off antiarrhythmic drugs at 1 year after a single-ablation procedure. A total of 156 patients (aged 59±9 years; 136 males; AF duration, 47±50 months) participated (arm 1, 55 patients; arm 2, 50 patients; arm 3, 51 patients). Procedural outcomes (procedure, fluoroscopy, and PVI times) were comparable between the 3 arms. More lesions were required to target non-PV trigger sites than a complex fractionated electrogram (33±9 versus 22±9; P <0.001). The primary end point was achieved in 71 patients and was worse in arm 3 (29%) compared with arm 1 (49%; P =0.04) and arm 2 (58%; P =0.004). Conclusions— These data suggest that additional substrate modification beyond PVI does not improve single-procedure efficacy in patients with persistent AF. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00379301.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3